The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Swiss drug major Novartis has announced new analyses from pivotal Phase III registration studies showing Xolair (omalizumab) helps patients with chronic spontaneous urticaria achieve significant improvements in quality of life measures. 12 June 2015
In draft guidance issued today for consultation, the UK Institute for Health can care Excellence (NICE) has asked Danish CNS drug specialist Lundbeck to provide more information about its drug vortioxetine (trade name Brintellix) for treating major depressive episodes in adults. 10 June 2015
Danish pharma company LEO Pharma has announced new data showing Enstilar in the treatment of psoriasis vulgaris provides rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis. 9 June 2015
The Scottish Medicines Consortium has issued positive advice for Cosentyx (secukinumab) from Novartis for the treatment of moderate to severe plaque psoriasis. 8 June 2015
The National Institute for Health and care Excellence (NICE) today issued guidance recommending Xolair (omalizumab) as an option for treating severe chronic spontaneous urticaria (also known as hives) in some adults and young people aged 12 years and over. 8 June 2015
The UK’s National Institute for Health and Care Excellence (NICE) has today issued a Final Appraisal Determination (FAD) recommending Cosentyx (secukinumab) from Swiss drug major Novartis for use on the National Health Service for the treatment of severe plaque psoriasis. 29 May 2015
Japanese drug major Chugai Pharmaceutical has submitted a New Drug Application to Japan’s Ministry of Health, Labor and Welfare for a combination topical drug preparation of maxacalcitol and betamethasone butyrate propionate (Development Code: M8010). 26 May 2015
Amgen said on Friday it has commenced termination of its participation in the co-development and commercialization of brodalumab with Anglo-Swedish pharma major AstraZeneca. 25 May 2015
Belgium-based biotech firm arGEN-X N (Euronext Brussels: ARGX) has entered into an alliance with independent Danish dermatology specialist LEO Pharma. 21 May 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined two dossier relating to US biotech firm Celgene’s Otezla (apremilast) as to whether this drug offers an added benefit over the respective appropriate comparator therapy. 19 May 2015
The US Food and Drug Administration has approved KYTHERA Biopharmaceuticals’ Kybella (deoxycholic acid), a treatment for adults with moderate-to-severe fat below the chin, known as submental fat. 30 April 2015
USA-based Antares Pharma says it has regained US marketing rights to Otrexup (methotrexate) injection for subcutaneous use for the psoriasis indication through the termination of an exclusive promotion and marketing agreement with independent Danish dermatology specialist Leo Pharma 30 April 2015
US pharma major Eli Lilly says that the investigational drug ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. 20 April 2015
Indian drug major Dr Reddy's Laboratories and its subsidiary, Promius Pharma, have filed three 505(b)(2) New Drug Applications with the US Food and Drug Administration. 8 April 2015
US clinical-stage firm Brickell Biotech has signed an exclusive license and development agreement for BBI-4000 with Japanese drugmaker Kaken Pharmaceutical. 2 April 2015
In line with its strategic focus, UCB has entered an agreement with Indian drugmaker Dr Reddy’s (BSE: 500359) to sell its established brands. 1 April 2015
Shares in inflammatory and cancer specialist Can-Fite slid more than 60% following the announcement that its experimental CF101 did not meet its primary endpoint in a Phase II/III study. 31 March 2015
Swiss drugmaker Galderma has received a positive outcome of the European Decentralized Procedure (DCP) for Soolantra (ivermectin) Cream 10mg/g for the once-daily topical treatment of inflammatory lesions of papulopustular rosacea in adult patients. 29 March 2015
Dermatology biotech company Signum Dermalogix has entered into an agreement with Dermata Therapeutics to develop a tropical product to treat rosacea. 25 March 2015